BMO Capital analyst Keith Bachman says that while there were both positives and negatives on Splunk's quarter, he retains his positive view on the shares given the "very solid demand metrics." Consistent with the concerns he raised previously, cash flow metrics deteriorated, given changes in contract structures. However, Bachman believes that "solid" margins and growth will enable cash flow metrics to improve, though he acknowledges at a gradual pace. He reiterates an Outperform rating on the shares, while lowered his price target on the stock to $155 from $157.

New option listings for April 23rd include Express Inc (EXPRQ). Option delistings effective April 23rd include PGT Innovations Inc (PGTI), NGM Biopharmaceuticals Inc (NGM), Karuna Therapeutics Inc (KRTX), KINNATE BIOPHARMA INC (KNTE), Daseke Inc (DSKE), Tritium Dcfc Ltd (DCFC), Xtrackers MSCI All China Equity ETF (CN), CymaBay Therapeutics Inc (CBAY), Alteryx Inc (AYX), XTRACKERS MSCI CHINA A INCLUSION EQUITY ETF (ASHX), Recro Pharma, Inc. (SCTL), Splunk Inc (SPLK), and Textainer Group Holdings Limited (TGH).